Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Patients With EoE Benefit From Systemic Treatment Regardless of Esophageal Dilation History
May 10th 2023Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.
Read More
Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC
May 9th 2023An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.
Read More
Certain Comorbidities May Predict Cardiovascular Event Risk After ADT for Prostate Cancer
May 5th 2023The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.
Read More
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Read More
Dr Jeffrey Lancet Discusses the Evolving Therapy Landscape of AML
May 4th 2023Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Read More
For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski
May 4th 2023Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).
Read More
Patients With Prostate Cancer Most Concerned With ADT Cost, Delivery Method
May 4th 2023A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.
Read More
Liquid and Tissue Biopsy Can Be Complementary in NSCLC, Says Dr Mark Socinski
April 29th 2023Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).
Read More
Value-Based Care: Is It Possible for All Providers to Succeed?
April 29th 2023Craig D. Pederson, principal at Insight Health Care Partners, discussed the evolving landscape of value-based care and challenges to implementation from the provider perspective during his keynote presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.
Read More
How Chronic Care Management Can Benefit Providers and Patients
April 28th 2023A session led by Irina Koyfman, DNP, NP-C, RN, at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 detailed the potential of chronic care management billing for physicians who are not currently doing it and recommendations for optimizing the process.
Read More
Interventions for Successful Implementation of Value-Based Care
April 28th 2023In a presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023, Robert L. Waterhouse Jr, MD, MBA, HSM, chief medical officer at Baylor Scott & White Quality Alliance, discussed the challenges of value-based care implementation and how to overcome them.
Read More
Highlighting Opportunities for Progress in a Changing Health Care Landscape
April 28th 2023Some of the health care transformations that were forced by the COVID-19 pandemic could continue to benefit patients and the health care system, Jacques Sokolov, MD, said during his keynote address at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.
Read More
Dr Jeffrey Lancet on Treatment Considerations in the Changing AML Therapy Landscape
April 28th 2023Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).
Read More
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).
Read More
Dr Jacque Sokolov Discusses Health Care Transformation Ahead of NAMCP Spring Managed Care Forum 2023
April 24th 2023Jacque Sokolov, MD, president and chairman at SSB Solutions, previews his keynote presentation and discusses the unique, shifting health care atmosphere leading into the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.
Read More
Unified Definition of "High-Risk" Is Needed for Multiple Myeloma Trials, Study Says
April 22nd 2023A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.
Read More
Study Suggests Use of Active Surveillance for Prostate Cancer Is Increasing
April 21st 2023The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.
Read More
Investigational Drug Could Improve Stem Cell Collection for ASCT
April 18th 2023Adding motixafortide to standard stem cell mobilization therapy for autologous hematopoietic stem cell transplantation (ASCT) significantly improved collection success rates vs standard therapy plus a placebo in a phase 3 trial of patients with multiple myeloma.
Read More
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
April 15th 2023A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Read More
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist
April 13th 2023Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.
Read More
Ixazomib Shows PFS Benefit Across Age and Frailty Subgroups in Multiple Myeloma
April 12th 2023A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.
Read More